Navigation Links
Adamas Pharmaceuticals Raises $40 Million in Series D Financing
Date:8/18/2009

erapy for influenza, which is designed to inhibit viral replication at multiple points in the virus proliferation pathway. TCAD therapy includes Adamas' investigational proprietary fixed-dose combination of amantadine and ribavirin, to be administered adjunctively with a neuraminidase inhibitor such as Tamiflu (oseltamivir phosphate, Roche). Preclinical data indicate that the in vitro combination of these drugs, each with their own mechanism of action, act synergistically to provide a much higher level of antiviral activity than single or double drug combination therapies. In in vitro studies to date, TCAD therapy also has been found to provide greater antiviral activity across multiple strains of influenza, even those resistant to single pharmaceutical agents. Adamas is accelerating development of its TCAD therapy for influenza A by conducting a Phase 2 clinical trial in the Southern Hemisphere where the novel influenza A/H1N1 pandemic is active, and is preparing to initiate a clinical study of TCAD therapy for influenza A in North America during this upcoming flu season.

Dr. Went added, "Our Board of Directors welcomes George Rehm and David Mahoney, whose diverse expertise and perspectives will help drive Adamas' global development, partnering and US commercial planning strategies. We look forward to their contributions to our goal of developing and commercializing pharmaceutical products that improve health outcomes."

George M. Rehm is a Managing Partner of aeris CAPITAL AG in Switzerland and has over twenty five years experience as a lawyer and executive in international licensing, technology transfer, investment and privatization transactions, involving the US, Europe and Asia, prior to commencing his current career in private equity. Currently, he holds board seats in numerous portfolio companies. Mr. Rehm remains of counsel to the Munich, Heidelberg and Berlin law firm of Weitnauer Partners. He rec
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results
2. Hisamitsu Pharmaceutical Announces Expiration of HSR Waiting Period for Its Proposed Acquisition of Noven Pharmaceuticals
3. Mylan Pharmaceuticals Receives Final FDA Report and Reaffirms Its 48-Year Exemplary Record of Quality
4. Endo Pharmaceuticals Announces Resignation of Chief Operating Officer
5. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
6. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
7. Video: Provectus Pharmaceuticals Updates Shareholders On 2009 Year-To-Date Accomplishments
8. Vion Pharmaceuticals Reports 2009 Second Quarter And Six-Month Results
9. DUSA Pharmaceuticals Reports Second Quarter 2009 Corporate Highlights and Financial Results
10. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
11. Jazz Pharmaceuticals to Announce Second Quarter Financial Results on August 11, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 From November 24, 2014, ... for the year 2014 in its Goa retreat . ... Through the Indian winters, from November to March, Siddhi Yoga ... beach of Arambol, Goa. The Goa training sessions will conclude ... of yoga teacher training, the 10th intake is also a ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 The ... ski club in Southern Vermont’s Deerfield Valley, announced today ... inspired by classic rock songs. , Three time ... with a private concert followed by a trail naming ... new trail names include: “I’m Alright” the theme song ...
(Date:12/19/2014)... Randy Dotinga ... News) -- Common painkillers, including ibuprofen, might slightly reduce ... researchers say. Use of ibuprofen (Advil, Motrin) and ... cell skin cancer by 15 percent, the researchers concluded ... is usually caused by sun exposure. ...
(Date:12/17/2014)... (PRWEB) December 17, 2014 Dr. Myo Nwe ... Weight Loss Diet of the Future” and co-founder of the ... her book, Dr. Nwe takes a broad look at the ... hold up under scientific scrutiny. On film and in television ... emphasized mostly toward the social aspects and played for basic ...
(Date:12/17/2014)... In its comprehensive analysis of medical ... Claim Review division have recently identified out-of-network and medical ... savings are achieved on behalf of employer-clients. , ... in savings to Argus each year, with a total ... by Tom Doney, Cypress president and CEO, these in-depth ...
Breaking Medicine News(10 mins):Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 2Health News:Siddhi Yoga’s 10th intake of YTT started in Goa on November 24, 2014 3Health News:The Hermitage Club Officially Names Four Ski Trails after Iconic Rock Songs by Grammy Award Winner Kenny Loggins 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Obesity Should Not Be a Hollywood Punchline, Weight Loss Doc Says 2Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2
... Ready or not, the holiday season,is here. The ... and pies, merry-making eggnog and potato latkes,and then New ... Super Bowl,buffalo wings and Valentine,s Day chocolates to contend ... holiday cooking and,feasting., Enter Helene Phillips, the mind, ...
... TeamHealth Inc.,s parent,company, Team Finance LLC (the "Company") ... 30, 2008., The Company previously announced the ... and substantially completed the disposal,of this business line ... with,relevant accounting guidance, the results of the anesthesia ...
... Of $9 million appropriated by,the Texas legislature ... of automated external defibrillators (AEDs), $3.5 million remains,unclaimed. ... AED purchase under,the reimbursement program until the November ... used by lay people with CPR training,to resuscitate ...
... analysis of 33 research projects , , MONDAY, Nov. 10 (HealthDay ... as beta blockers has concluded that they are not useful ... using beta blockers for non-coronary surgery may actually increase the ... conducted the study -- known as a meta-analysis -- recommend ...
... Primary Care Physician Recruitment, ORLANDO, Fla., Nov. 10 ... shortage - with primary care,being especially hard hit. As ... this shortage promises to get worse with major,repercussions for ... is working to address this issue with a new ...
... with Top-Ranked ... ... social,network for physicians practicing in the U.S., is hosting a ... of the causes and consequences of the current,economic downturn and ...
Cached Medicine News:Health News:Tips for Maintaining Your Physique While Enjoying Your Favorite Treats 2Health News:Tips for Maintaining Your Physique While Enjoying Your Favorite Treats 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 2Health News:Team Finance LLC Announces Third Quarter 2008 Results 3Health News:Team Finance LLC Announces Third Quarter 2008 Results 4Health News:Team Finance LLC Announces Third Quarter 2008 Results 5Health News:Team Finance LLC Announces Third Quarter 2008 Results 6Health News:Team Finance LLC Announces Third Quarter 2008 Results 7Health News:Team Finance LLC Announces Third Quarter 2008 Results 8Health News:Team Finance LLC Announces Third Quarter 2008 Results 9Health News:$3.5 Million in Reimbursements for Purchases of Automated External Defibrillators (AEDs) for Texas Schools Still Unclaimed With Deadline Approaching 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 2Health News:Beta Blocker Use Questioned in Non-Heart Surgery 3Health News:AMA Works to Reverse Primary Care Physician Shortage 2Health News:iMedExchange Responses to Financial Crisis 2
(Date:12/19/2014)... 18, 2014   Aratana Therapeutics, Inc . ... focused on the licensing, development and commercialization of ... results from its pivotal field study of AT-001 ... in dogs with osteoarthritis.  In the study, dogs ... that were statistically significant compared to placebo (p<0.05) ...
(Date:12/17/2014)... SAN DIEGO , Dec. 17, 2014 ... and Volcano Corporation (NASDAQ: VOLC ), a global ... today announced that they have entered into a definitive merger ... offer to acquire all of the issued and outstanding shares ... equity purchase price of USD 1 billion (approx. EUR 800 ...
(Date:12/17/2014)... , Dec. 17, 2014  Strategic Health Services, ... software solutions, today announced a strategic agreement with QualCare, ... New Jersey regional marketplace.  This agreement ... the health and wellness solutions QualCare brings to its ... the surrounding region. QualCare plans cover ...
Breaking Medicine Technology:Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 2Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 3Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 4Aratana Therapeutics Announces Positive Top-Line Results from AT-001 Pivotal Field Study in Client-Owned Dogs with Osteoarthritis 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 2Strategic Health Services to collaborate with QualCare on Population Health and Wellness Technology for QualCare Members 3
... Reportlinker.com announces that a new market research ... Strategic Analysis of End-user Preferences in the ... http://www.reportlinker.com/p0258289/Strategic-Analysis-of-End-user-Preferences-in-the-US-Stem-Cell-Research-Tools-Markets.html The primary ... perceptions of tools and technologies currently at the ...
... Safety and Clinical Benefits of Radioactive Microspheres in... -- ROME, August 19, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
Cached Medicine Technology:Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets 2Reportlinker Adds Strategic Analysis of End-user Preferences in the U.S. Stem Cell Research Tools Markets 3Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 2Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 3Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 4Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 5Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 6Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 7Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 8Multi-centre Phase II Trial Reports Safety and Clinical Benefits of Radioactive Microspheres in Patients with Colorectal Cancer Liver Metastases who have Failed Chemotherapy 9
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: